Ignite Creation Date:
2024-05-06 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06136351
Status:
RECRUITING
Last Update Posted:
2023-11-29
First Post:
2023-09-25
Brief Title:
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in Elderly or TP53 Alterations or Chemotherapy Intolerance Patients With Newly Diagnosed Mantle Cell Lymphoma
Sponsor:
Ruijin Hospital
Organization:
Ruijin Hospital
Study Overview
Official Title:
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in Elderly or TP53 Alterations or Chemotherapy Intolerance Patients With Newly Diagnosed Mantle Cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of Zanubrutinib given in combination with bendamustine and rituximab in elderly or TP53 alterations or chemotherapy intolerance patients with newly diagnosed mantle cell lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None